The role of complement in C3 glomerulopathy

被引:69
|
作者
Zipfel, Peter F. [1 ,2 ]
Skerka, Christine [1 ]
Chen, Qian [1 ]
Wiech, Thorsten [3 ]
Goodship, Tim [4 ]
Johnson, Sally [4 ]
Fremeaux-Bacchi, Veronique [5 ,6 ]
Nester, Clara [7 ]
Rodriguez de Cordoba, Santiago [8 ,9 ]
Noris, Marina [10 ]
Pickering, Matthew [11 ]
Smith, Richard [7 ]
机构
[1] Leibniz Inst Nat Prod Res & Infect Biol, D-07745 Jena, Germany
[2] Univ Jena, D-07745 Jena, Germany
[3] Univ Hosp Hamburg Eppendorf, Inst Pathol, Hamburg, Germany
[4] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[5] Hosp European Georges Pompidou, Assistance Publ Hop Paris, Paris, France
[6] Cordelier Res Ctr, Complement & Dis Team, INSERM, UMRS 1138, Paris, France
[7] Univ Iowa, Carver Coll Med, Otolaryngol, Iowa City, IA 52242 USA
[8] Ctr Invest Biol, Dept Med Celular & Mol, Madrid 28040, Spain
[9] Ctr Invest Biol, Ciber Enfermedades Raras, Madrid 28040, Spain
[10] Mario Negri Inst Pharmacol Res, Bergamo, Italy
[11] Univ London Imperial Coll Sci Technol & Med, Dept Med, London SW7 2AZ, England
关键词
Complement C3 glomerulopathy; MPGN membranoproliferative; Dense deposit diseases; C3 nephritic factor; DENSE DEPOSIT DISEASE; HEMOLYTIC-UREMIC SYNDROME; FACTOR-H-AUTOANTIBODIES; GLOMERULONEPHRITIS TYPE-II; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; ALTERNATIVE PATHWAY; NEPHRITIC FACTOR; MACULAR DEGENERATION; NEISSERIA-GONORRHOEAE; BINDING-AFFINITY;
D O I
10.1016/j.molimm.2015.03.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
C3 glomerulopathy describes a spectrum of disorders with glomerular pathology associated with C3 cleavage product deposition and with defective complement action and regulation (Fakhouri et al., 2010; Sethi et al., 2012b). Kidney biopsies from these patients show glomerular accumulation or deposition of C3 cleavage fragments, but no or minor deposition of immunoglobulins (Appel et al., 2005; D'Agati and Bomback, 2012; Servais et al., 2007; Sethi and Fervenza, 2011). At present the current situation asks for a better definition of the underlining disease mechanisms, for precise biomarkers, and for a treatment for this disease. The complement system is a self activating and propelling enzymatic cascade type system in which inactive, soluble plasma components are activated spontaneously and lead into an amplification loop (Zipfel and Skerka, 2009). Activation of the alternative pathway is spontaneous, occurs by default, and cascade progression leads to amplification by complement activators. The system however is self-controlled by multiple regulators and inhibitors, like Factor H that control cascade progression in fluid phase and on surfaces. The activated complement system generates a series of potent effector components and activation products, which damage foreign-, as well as modified self cells, recruit innate immune cells to the site of action, coordinate inflammation and the response of the adaptive immune system in form of B cells and T lymphocytes (Kohl, 2006; Medzhitov and Janeway, 2002; Ogden and Elkon, 2006; Carroll, 2004; Kemper and Atkinson, 2007; Morgan, 1999; Muller-Eberhard, 1986; Ricklin et al., 2010). Complement controls homeostasis and multiple reactions in the vertebrate organism including defense against microbial infections (Diaz-Guillen et al., 1999; Mastellos and Lambris, 2002; Nordahl et al., 2004; Ricklin et al., 2010). In consequence defective control of the spontaneous self amplifying cascade or regulation is associated with numerous human disorders (Ricklin and Lambris, 2007; Skerka and Zipfel, 2008; Zipfel et al., 2006). Understanding the exact action and regulation of this sophisticated homeotic cascade system is relevant to understand disease pathology of various complement associated human disorders. Furthermore this knowledge is relevant for a better diagnosis and appropriate therapy. At present diagnosis of C3 glomerulopathy is primarily based on the kidney biopsy, and histological, immmunohistological and electron microscopical evaluation (D'Agati and Bomback, 2012; Fakhouri et al., 2010; Medjeral-Thomas et al., 2014a,b; Sethi et al., 2012b). The challenge is to define the actual cause of the diverse glomerular changes or damages, to define how C3 deposition results in the reported glomerular changes, the location of the cell damage and the formation of deposits. (C) 2015 Published by Elsevier Ltd.
引用
收藏
页码:21 / 30
页数:10
相关论文
共 50 条
  • [1] Complement inhibition in C3 glomerulopathy
    Nester, Carla M.
    Smith, Richard J. H.
    [J]. SEMINARS IN IMMUNOLOGY, 2016, 28 (03) : 241 - 249
  • [2] Circulating Complement Levels and C3 Glomerulopathy
    Fervenza, Fernando C.
    Sethi, Sanjeev
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 9 (11): : 1829 - 1831
  • [3] Treatment of C3 Glomerulopathy with Complement Blockers
    Vivarelli, Marina
    Emma, Francesco
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2014, 40 (04): : 472 - 477
  • [4] Alternative pathway complement activation in C3 glomerulopathy
    Volokhina, Elena
    Goertz, Joop
    van der Velden, Thea
    van de Kar, Nicole
    Mollnes, Tom Eirik
    van den Heuvel, Lambertus
    [J]. MOLECULAR IMMUNOLOGY, 2015, 67 (01) : 194 - 195
  • [5] Defining the Complement Biomarker Profile of C3 Glomerulopathy
    Zhang, Yuzhou
    Nester, Carla M.
    Martin, Bertha
    Skjoedt, Mikkel-Ole
    Meyer, Nicole C.
    Shao, Dingwu
    Borsa, Nicolo
    Palarasah, Yaseelan
    Smith, Richard J. H.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 9 (11): : 1876 - 1882
  • [6] ALTERNATIVE PATHWAY COMPLEMENT ACTIVATION IN C3 GLOMERULOPATHY
    Volokhina, Elena
    Michels, Marloes
    Goertz, Joop
    Wetzels, Jack
    Van de Kar, Nicole
    Mollnes, Tom Eirik
    Van den Heuvel, Lambertus
    [J]. PEDIATRIC NEPHROLOGY, 2015, 30 (09) : 1645 - 1645
  • [7] Genetic analysis of the complement pathway in C3 glomerulopathy
    Zhao, Weiwei
    Ding, Yin
    Lu, Jianping
    Zhang, Tao
    Chen, Dacheng
    Zhang, Haitao
    Zeng, Caihong
    Liu, Zhihong
    Chen, Huimei
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 (11) : 1919 - 1927
  • [8] C3 GLOMERULOPATHY: AN UPDATE ON COMPLEMENT GENETIC DRIVERS
    Lucientes Continente, Laura
    Caravaca Fontan, Fernando
    Gutierrez Tenorio, Josue
    Marquez Tirado, Barbara
    Arjona, Emilia
    Garcia Fernandez, Jesus
    Pinto, Sheila
    Rodriguez de Cordoba, Santiago
    Praga Terente, Manuel
    Goicoechea de Jorge, Elena
    [J]. MOLECULAR IMMUNOLOGY, 2019, 114 : 493 - 493
  • [9] ROLE OF RENIN IN C3 GLOMERULOPATHY
    Martin, Bertha
    Smith, Richard J. H.
    Nester, Carla
    Zhang, Yuzhou
    [J]. MOLECULAR IMMUNOLOGY, 2019, 114 : 494 - 494
  • [10] C3 glomerulopathy: A new complement-based entity
    de Lorenzo, A.
    Tallon, S.
    Hernandez-Sevillano, B.
    de Arriba, G.
    [J]. REVISTA CLINICA ESPANOLA, 2014, 214 (05): : 266 - 274